Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients
BACKGROUND: Monitoring immunosuppressant levels, such as mycophenolic acid (MPA), cyclosporin A (CsA), and tacrolimus (TAC), in peripheral blood mononuclear cells (PBMCs) could be useful in organ transplant patients administered individualized therapy. The authors developed a liquid chromatography-tandem mass spectrometry assay technique to simultaneously determine immunosuppressant levels in PBMCs and assess their pharmacokinetics in Chinese renal allograft recipients.
METHODS: PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 μm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min.
RESULTS: The calibration curves of MPA, CsA, and TAC had a linear range (ng·mL): 0.098-39.2 (r = 0.9987), 0.255-102 (r = 0.9969), and 0.028-11.2 (r = 0.9993), respectively. The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively. The within-day and between-day coefficients of variation were <15%. The AUC0-12 of MPA in PBMCs correlated well with those in plasma. The level of MPA, CsA, and TAC in PBMCs might be more stable during dosing interval.
CONCLUSIONS: The derived liquid chromatography-tandem mass spectrometry assay is suitable for simultaneously monitoring different immunosuppressants in PBMCs. Pharmacokinetic of MPA, CsA, and TAC displayed considerable interindividual variability. Intracellular monitoring of immunosuppressants may facilitate individualized therapy for renal allograft recipients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
Therapeutic drug monitoring - 42(2020), 5 vom: 01. Okt., Seite 686-694 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chen, Bing [VerfasserIn] |
---|
Links: |
---|
Themen: |
83HN0GTJ6D |
---|
Anmerkungen: |
Date Completed 18.08.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/FTD.0000000000000765 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314317732 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314317732 | ||
003 | DE-627 | ||
005 | 20231225152453.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/FTD.0000000000000765 |2 doi | |
028 | 5 | 2 | |a pubmed24n1047.xml |
035 | |a (DE-627)NLM314317732 | ||
035 | |a (NLM)32858576 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chen, Bing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.08.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: Monitoring immunosuppressant levels, such as mycophenolic acid (MPA), cyclosporin A (CsA), and tacrolimus (TAC), in peripheral blood mononuclear cells (PBMCs) could be useful in organ transplant patients administered individualized therapy. The authors developed a liquid chromatography-tandem mass spectrometry assay technique to simultaneously determine immunosuppressant levels in PBMCs and assess their pharmacokinetics in Chinese renal allograft recipients | ||
520 | |a METHODS: PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 μm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min | ||
520 | |a RESULTS: The calibration curves of MPA, CsA, and TAC had a linear range (ng·mL): 0.098-39.2 (r = 0.9987), 0.255-102 (r = 0.9969), and 0.028-11.2 (r = 0.9993), respectively. The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively. The within-day and between-day coefficients of variation were <15%. The AUC0-12 of MPA in PBMCs correlated well with those in plasma. The level of MPA, CsA, and TAC in PBMCs might be more stable during dosing interval | ||
520 | |a CONCLUSIONS: The derived liquid chromatography-tandem mass spectrometry assay is suitable for simultaneously monitoring different immunosuppressants in PBMCs. Pharmacokinetic of MPA, CsA, and TAC displayed considerable interindividual variability. Intracellular monitoring of immunosuppressants may facilitate individualized therapy for renal allograft recipients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Cyclosporine |2 NLM | |
650 | 7 | |a 83HN0GTJ6D |2 NLM | |
650 | 7 | |a Mycophenolic Acid |2 NLM | |
650 | 7 | |a HU9DX48N0T |2 NLM | |
650 | 7 | |a Tacrolimus |2 NLM | |
650 | 7 | |a WM0HAQ4WNM |2 NLM | |
700 | 1 | |a Lu, Jia-Qian |e verfasserin |4 aut | |
700 | 1 | |a Shao, Kun |e verfasserin |4 aut | |
700 | 1 | |a Zhai, Xiao-Hui |e verfasserin |4 aut | |
700 | 1 | |a An, Hui-Min |e verfasserin |4 aut | |
700 | 1 | |a Shi, Hao-Qiang |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Pei-Jun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Therapeutic drug monitoring |d 1993 |g 42(2020), 5 vom: 01. Okt., Seite 686-694 |w (DE-627)NLM000962295 |x 1536-3694 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2020 |g number:5 |g day:01 |g month:10 |g pages:686-694 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/FTD.0000000000000765 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 42 |j 2020 |e 5 |b 01 |c 10 |h 686-694 |